2 Oorjita research notes discuss Zydus Lifesciences.
Indian pharma experiencing bifurcation - diversified players (Lupin, Cipla) thriving; single-product-dependent players (Natco with Revlimid) struggling.
Strong YoY growth in revenue and profitability, margin expansion, and operational efficiency despite loss of PLI benefits.
